TY - JOUR
T1 - Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort
AU - Doyle, Joseph Samuel
AU - Deterding, Katja
AU - Grebely, Jason
AU - Wedemeyer, Heiner
AU - Sacks-Davis, Rachel
AU - Spelman, Tim
AU - Matthews, Gail V
AU - Rice, Thomas M
AU - Morris, Meghan
AU - McGovern, Barbara H
AU - Kim, Arthur Y
AU - Bruneau, Julie
AU - Lloyd, Andrew R
AU - Page, Kimberly A
AU - Manns, Michael Peter
AU - Hellard, Margaret Elena
AU - Dore, Gregory J
PY - 2015
Y1 - 2015
N2 - Pegylated interferon therapy is highly effective in recently acquired HCV. The optimal timing of treatment, regimen and influence of host factors remains unclear. We aimed to measure sustained virological response (SVR) during recent HCV infection and identify predictors of response. Data were from five prospective cohorts of high-risk individuals in Australia, Canada, Germany and the United States. Individuals with acute or early chronic HCV who commenced pegylated interferon therapy were included. The main outcome was SVR, and predictors were assessed using logistic regression. Among 516 with documented recent HCV infection, 237 were treated (pegylated interferon n = 161; pegylated interferon/ribavirin n = 76) (30 female, median age 35 years, 56 ever injected drugs, median duration of infection 6.2 months). Sixteen per cent (n = 38) were HIV/HCV co-infected. SVR among those with HCV mono-infection was 64 by intention to treat; SVR was 68 among HCV/HIV co-infection. Independent predictors of SVR in HCV mono-infection were duration of HCV infection (the odds of SVR declined by 8 per month of infection, aOR 0.92, 95 CI 0.85-0.99, P = 0.033), IFNL4 genotype (adjusted OR 2.27, 95 CI 1.13-4.56, P = 0.021), baseline HCV RNA
AB - Pegylated interferon therapy is highly effective in recently acquired HCV. The optimal timing of treatment, regimen and influence of host factors remains unclear. We aimed to measure sustained virological response (SVR) during recent HCV infection and identify predictors of response. Data were from five prospective cohorts of high-risk individuals in Australia, Canada, Germany and the United States. Individuals with acute or early chronic HCV who commenced pegylated interferon therapy were included. The main outcome was SVR, and predictors were assessed using logistic regression. Among 516 with documented recent HCV infection, 237 were treated (pegylated interferon n = 161; pegylated interferon/ribavirin n = 76) (30 female, median age 35 years, 56 ever injected drugs, median duration of infection 6.2 months). Sixteen per cent (n = 38) were HIV/HCV co-infected. SVR among those with HCV mono-infection was 64 by intention to treat; SVR was 68 among HCV/HIV co-infection. Independent predictors of SVR in HCV mono-infection were duration of HCV infection (the odds of SVR declined by 8 per month of infection, aOR 0.92, 95 CI 0.85-0.99, P = 0.033), IFNL4 genotype (adjusted OR 2.27, 95 CI 1.13-4.56, P = 0.021), baseline HCV RNA
UR - http://onlinelibrary.wiley.com/doi/10.1111/jvh.12429/epdf
U2 - 10.1111/jvh.12429
DO - 10.1111/jvh.12429
M3 - Article
VL - 22
SP - 1020
EP - 1032
JO - Journal of Viral Hepatitis
JF - Journal of Viral Hepatitis
SN - 1352-0504
IS - 12
ER -
